The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

Although oral treatments such as Janus kinase inhibitors ... achieved a validated Investigator’s Global Assessment for Atopic Dermatitis score of 0-1 with at least a two-point reduction from ...

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...